Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody

Infection and Immunity

Volumn 76, Issue 10, 2008, Pages 4469-4478

  Sauter, Kristin A D ^a   Melton Celsa, Angela R ^b   Larkin, Kay ^c   Troxell, Megan L ^c   O'Brien, Alison D ^b   Magun, Bruce E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11E10 MONOCLONAL ANTIBODY; CHEMOKINE; CREATININE; CYTOKINE; FIBRINOGEN; MONOCLONAL ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG; VEROTOXIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; GLOMERULAR DYSFUNCTION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; KIDNEY FUNCTION; LEUKOPENIA; LYMPHOCYTE; MALE; MOUSE; NEUTROPHIL; NEUTROPHILIA; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SERUM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTITOXINS; BLOOD UREA NITROGEN; CHILD; CREATININE; CYTOKINES; FIBRINOGEN; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; LEUKOPENIA; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; PROTEINURIA; SHIGA TOXIN 2;

EID: 53649099970     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00592-08     Document Type: Article

References (64)

1. Andreoli, S. P., H. Trachtman, D. W. Acheson, R. L. Siegler, and T. G. Obrig. 2002. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr. Nephrol. 17:293-298.
2. Baker, D. R., R. A. Moxley, and D. H. Francis. 1997. Variation in virulence in the gnotobiotic pig model of O157:H7 Escherichia coli strains of bovine and human origin. Adv. Exp. Med. Biol. 412:53-58.
3. Barrett, T. J., M. E. Potter, and I. K. Wachsmuth. 1989. Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect. Immun. 57:3434-3437.
4. Cherla, R. P., S. Y. Lee, P. L. Mees, and V. L. Tesh. 2006. Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line. J. Leukoc. Biol. 79:397-407.
5. Cohen, A., G. E. Hannigan, B. R. Williams, and C. A. Lingwood. 1987. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J. Biol. Chem. 262:17088-17091.
6. Dowling, T. C., P. A. Chavaillaz, D. G. Young, A. Melton-Celsa, A. O'Brien, C. Thuning-Roberson, R. Edelman, and C. O. Tacket. 2005. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody cαStx2 administered intravenously to healthy adult volunteers. Antimicrob. Agents Chemother. 49:1808-1812.
7. Drabkin, D. L. 1971. Heme binding and transport - a spectrophotometric study of plasma glycoglobulin hemochromogens. Proc. Natl. Acad. Sci. USA 68:609-613.
8. Edwards, A. C., A. R. Melton-Celsa, K. Arbuthnott, S. J. R., C. K. Schmitt, H. C. Wong, and A. D. O'Brien. 1998. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against Escherichia coli toxins Stx1 and Stx2, p. 388-392. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, DC.
9. Endo, Y., K. Mitsui, M. Motizuki, and K. Tsurugi. 1987. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J. Biol. Chem. 262:5908-5912.
10. Endo, Y., and K. Tsurugi. 1987. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J. Biol. Chem. 262:8128-8130.
11. Endo, Y., K. Tsurugi, T. Yutsudo, Y. Takeda, T. Ogasawara, and K. Igarashi. 1988. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 171:45-50.
12. Foster, G. H., C. S. Armstrong, R. Sakiri, and V. L. Tesh. 2000. Shiga toxin-induced tumor necrosis factor alpha expression: requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases. Infect. Immun. 68:5183-5189.
13. Foster, G. H., and V. L. Tesh. 2002. Shiga toxin 1-induced activation of c-Jun NH(2)-terminal kinase and p38 in the human monocytic cell line THP-1: possible involvement in the production of TNF-alpha. J. Leukoc. Biol. 71: 107-114.
14. Fujii, J., Y. Kinoshita, T. Yutsudo, H. Taniguchi, T. Obrig, and S. I. Yoshida. 2001. Toxicity of Shiga toxin 1 in the central nervous system of rabbits. Infect. Immun. 69:6545-6548.
15. Gerber, A., H. Karch, F. Allerberger, H. M. Verweyen, and L. B. Zimmerhackl. 2002. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J. Infect. Dis. 186:493-500.
16. Guessous, F., M. Marcinkiewicz, R. Polanowska-Grabowska, S. Kongkhum, D. Heatherly, T. Obrig, and A. R. Gear. 2005. Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function. Infect. Immun. 73:8306-8316.
17. Habib, R. 1992. Pathology of the hemolytic uremic syndrome, p. 315-353. In B. S. Kaplan (ed.), Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Marcel Dekker, New York, NY.
18. Hughes, A. K., P. K. Stricklett, D. Schmid, and D. E. Kohan. 2000. Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int. 57:2350-2359.
19. Ikeda, M., S. Ito, and M. Honda. 2004. Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin. Pediatr. Nephrol. 19:485-489.
20. Inward, C. D., A. J. Howie, M. M. Fitzpatrick, F. Rafaat, D. V. Milford, C. M. Taylor, et al. 1997. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. Pediatr. Nephrol. 11:556-559.
21. Iordanov, M. S., D. Pribnow, J. L. Magun, T. H. Dinh, J. A. Pearson, S. L. Chen, and B. E. Magun. 1997. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol. Cell. Biol. 17:3373-3381.
22. Karpman, D., H. Connell, M. Svensson, F. Scheutz, P. Alm, and C. Svanborg. 1997. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J. Infect. Dis. 175:611-620.
23. Karpman, D., A. Hakansson, M. T. Perez, C. Isaksson, E. Carlemalm, A. Caprioli, and C. Svanborg. 1998. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect. Immun. 66:636-644.
24. Keepers, T. R., M. A. Psotka, L. K. Gross, and T. G. Obrig. 2006. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J. Am. Soc. Nephrol. 17:3404-3414.
25. Kita, E., Y. Yunou, T. Kurioka, H. Harada, S. Yoshikawa, K. Mikasa, and N. Higashi. 2000. Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7. Infect. Immun. 68:1207-1214.
26. Kolling, G. L., F. Obata, L. K. Gross, and T. G. Obrig. 2008. Immunohistologic techniques for detecting the glycolipid Gb(3) in the mouse kidney and nervous system. Histochem. Cell Biol. 130:157-164.
27. Korcheva, V., J. Wong, C. Corless, M. Iordanov, and B. Magun. 2005. Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome. Am. J. Pathol. 166:323-339.
28. Krautz-Peterson, G., S. Chapman-Bonofiglio, K. Boisvert, H. Feng, I. M. Herman, S. Tzipori, and A. S. Sheoran. 2008. Intracellular neutralization of Shiga toxin 2 by an A subunit-specific human monoclonal antibody. Infect. Immun. 76:1931-1939.
29. Lingwood, C. A. 1996. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 4:147-153.
30. Lingwood, C. A., H. Law, S. Richardson, M. Petric, J. L. Brunton, S. De Grandis, and M. Karmali. 1987. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem. 262:8834-8839.
31. Litalien, C., F. Proulx, M. M. Mariscalco, P. Robitaille, J. P. Turgeon, E. Orrbine, P. C. Rowe, P. N. McLaine, and E. Seidman. 1999. Circulating inflammatory cytokine levels in hemolytic uremic syndrome. Pediatr. Nephrol. 13:840-845.
32. Mariani-Kurkdjian, P., and E. Bingen. 1995. Hemolytic-uremic syndrome after verotoxin-producing Escherichia coli infection. Presse Med. 24:99-101. (In French.)
33. Melton-Celsa, A. R., and A. D. O'Brien. 2000. Shiga toxins of Shigella dysenteriae and Escherichia coli. Handb. Exp. Pharmacol. 145:385-406.
34. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70:612-619.
35. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Production and characterization of protective human antibodies against Shiga toxin 1. Infect. Immun. 70:5896-5899.
36. Obrig, T. G., T. P. Moran, and J. E. Brown. 1987. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem. J. 244:287-294.
37. O'Loughlin, E. V., and R. M. Robins-Browne. 2001. Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. Microbes Infect. 3:493-507.
38. Palermo, M., F. Alves-Rosa, C. Rubel, G. C. Fernandez, G. Fernandez-Alonso, F. Alberto, M. Rivas, and M. Isturiz. 2000. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Clin. Exp. Immunol. 119:77-83.
39. Palermo, M. S., M. F. Alves Rosa, N. Van Rooijen, and M. A. Isturiz. 1999. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Clin. Exp. Immunol. 116:462-467.
40. Paton, J. C., and A. W. Paton. 1998. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev. 11:450-479.
41. Perera, L. P., L. R. Marques, and A. D. O'Brien. 1988. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J. Clin. Microbiol. 26:2127-2131.
42. Proulx, F., E. G. Seidman, and D. Karpman. 2001. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr. Res. 50:163-171.
43. Ray, P. E., and X. H. Liu. 2001. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr. Nephrol. 16:823-839.
44. Richardson, S. E., T. A. Rotman, V. Jay, C. R. Smith, L. E. Becker, M. Petric, N. F. Olivieri, and M. A. Karmali. 1992. Experimental verocytotoxemia in rabbits. Infect. Immun. 60:4154-4167.
45. Rovin, B. H., and L. T. Phan. 1998. Chemotactic factors and renal inflammation. Am. J. Kidney Dis. 31:1065-1084.
46. Ruggenenti, P., M. Noris, and G. Remuzzi. 2001. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 60:831-846.
47. Rutjes, N. W., B. A. Binnington, C. R. Smith, M. D. Maloney, and C. A. Lingwood. 2002. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 62:832-845.
48. Sandvig, K. 2001. Shiga toxins. Toxicon 39:1629-1635.
49. Saxena, S. K., A. D. O'Brien, and E. J. Ackerman. 1989. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J. Biol. Chem. 264:596-601.
50. Sheoran, A. S., S. Chapman, P. Singh, A. Donohue-Rolfe, and S. Tzipori. 2003. Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect. Immun. 71: 3125-3130.
51. Sheth, K. J., H. M. Swick, and N. Haworth. 1986. Neurological involvement in hemolytic-uremic syndrome. Ann. Neurol. 19:90-93.
52. Siegler, R. L., T. J. Pysher, R. Lou, V. L. Tesh, and F. B. Taylor, Jr. 2001. Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome. Am. J. Nephrol. 21:420-425.
53. Smith, W. E., A. V. Kane, S. T. Campbell, D. W. Acheson, B. H. Cochran, and C. M. Thorpe. 2003. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect. Immun. 71:1497-1504.
54. Suzuki, K., K. Tateda, T. Matsumoto, F. Gondaira, S. Tsujimoto, and K. Yamaguchi. 2000. Effects of interaction between Escherichia coli verotoxin and lipopolysaccharide on cytokine induction and lethality in mice. J. Med. Microbiol. 49:905-910.
55. Taguchi, T., H. Uchida, N. Kiyokawa, T. Mori, N. Sato, H. Horie, T. Takeda, and J. Fujimoto. 1998. Verotoxins induce apoptosis in human renal tubular epithelium derived cells. Kidney Int. 53:1681-1688.
56. Takahashi, K., N. Funata, F. Ikuta, and S. Sato. 2008. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J. Neuroinflammation 5:11.
57. Teel, L. D., J. A. Daly, R. C. Jerris, D. Maul, G. Svanas, A. D. O'Brien, and C. H. Park. 2007. Rapid detection of Shiga toxin-producing Escherichia coli by optical immunoassay. J. Clin. Microbiol. 45:3377-3380.
58. Te Loo, D. M., V. W. van Hinsbergh, L. P. van den Heuvel, and L. A. Monnens. 2001. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J. Am. Soc. Nephrol. 12:800-806.
59. Tesh, V. L., J. A. Burris, J. W. Owens, V. M. Gordon, E. A. Wadolkowski, A. D. O'Brien, and J. E. Samuel. 1993. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 61:3392-3402.
60. Tzipori, S., A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic-uremic syndrome. Clin. Microbiol. Rev. 17:926-941.
61. Upadhyaya, K., K. Barwick, M. Fishaut, M. Kashgarian, and N. J. Siegel. 1980. The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics 65:115-120.
62. van Setten, P. A., V. W. van Hinsbergh, L. P. van den Heuvel, F. Preyers, H. B. Dijkman, K. J. Assmann, T. J. van der Velden, and L. A. Monnens. 1998. Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome. Pediatr. Res. 43:759-767.
63. Weiler-Guettler, H., P. D. Christie, D. L. Beeler, A. M. Healy, W. W. Hancock, H. Rayburn, J. M. Edelberg, and R. D. Rosenberg. 1998. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J. Clin. Investig. 101:1983-1991.
64. Yamagami, S., M. Motoki, T. Kimura, H. Izumi, T. Takeda, Y. Katsuura, and Y. Matsumoto. 2001. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 184:738-742.